On the Couch Marcus Today

In this episode of On the Couch, I catch up with the CEO of Highfield Resources, Ignacio Salazar.

We last spoke to Ignacio in December 2021, and plenty has happened since with the Muga Project in Northern Spain.

Ignacio is currently in Australia updating investors on the progress of permitting, construction and financing for this important project in the European fertiliser market.

Ignacio Salazar is an international executive with more than 30 years of experience in the natural resources industry. He has lived and worked in various countries in Europe and South America. Ignacio assumed the position of CEO of Highfield in July 2020, after coming from Orosur Mining, a Canadian gold mining company with operations in Colombia, Uruguay and Chile, which is listed in the London and Toronto stock markets, and in which he worked as CEO and CFO for 12 years.

Ignacio has extensive experience in the exploration, development, construction and operation of open pit and underground mines.

Grab a glass of Rioja and sit back and enjoy the conversation with Ignacio.

If you enjoyed this podcast, why not sign up for a free trial? Get access to expert insights and research and become a better investor.

There are also plenty of free podcasts from Marcus Today and the team covering daily updates, chats with fund managers and CEOs of companies that interest us.

Welcome to another episode of 'On the Couch' with myself, Henry Jennings from Marcus Today. In this episode we are talking lithium, and AGY Argosy in particular. I have as my guest Jerko Zuvela, the MD.
Jerko is a Chartered Professional Geologist having spent over 20 years in the mining and resources industry. He has held executive management roles for private and public resources companies, with operational and corporate experience in various commodities covering exploration, project development, business development, finance, commercial and corporate activities involved with projects in Australia, Asia, Africa and South America.Jerko has considerable experience in building junior resources companies and understands the requirements working within this sector, including fundamental parameters, strategic drivers and market requirements within the junior resources industry. Background on Rincon.
The Rincon Lithium Project currently comprises up to ~2,794 hectares of Mining Titles and mining easement landholdings at the Salar del Rincon in Salta Province, Argentina.Argosy currently has a 77.5% interest in the JV entity that owns Rincon Lithium Project - Puna Mining S.A., with the right to move to 90% ownership in consideration for funding Stage 3 development.
If you enjoyed this podcast, why not sign up for a free trial? Get access to expert insights and research and become a better investor.

There are also plenty of free podcasts from Marcus Today and the team covering daily updates, chats with fund managers and CEOs of companies that interest us.

In this episode of On the Couch, I am joined by the CEO of one of the hottest Bio tech stories around currently, Jon Pilcher from Neuren (NEU).

Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included its IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. 

He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.  He is a non-executive director of BTC Health.

Neuren Pharmaceuticals (NEU) is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
Neuren's lead product trofinetide (also known as NNZ-2566) is licensed to Acadia Pharmaceuticals for North America, with Neuren retaining all rights outside North America and full access to all data generated by Acadia.

If you enjoyed this podcast, why not sign up for a free trial? Get access to expert insights and research and become a better investor.

There are also plenty of free podcasts from Marcus Today and the team covering daily updates, chats with fund managers and CEOs of companies that interest us.

In this episode of 'On the Couch' Henry sits down with chartist, mentor and professional trader Louise Bedford to talk candlesticks, trading psychology and what it takes to be a profitable trader. 

Louise is a fantastic presenter and communicator and has changed many people's lives through her mentoring and trading programs.

Louise is the founder of the Trading Game website and runs her own weekly trading podcast called Talking Trading. She is also a best-selling author of five books on the stockmarket and a behavioural finance expert with degrees in Psychology and Business. She holds an Australian Financial Services Licence.

Her best selling books include, Trading Secrets, Charting Secrets, Let the Trade Wins Flow, The Secret of Candlestick Charting and The Secret of Writing Options.

You can catch up with Louise on www.tradinggame.com.au for her own weekly podcast and trader education.

This is one of the most interesting and informative podcasts we have done on trading, and what it takes to be successful. Highly recommended.

Welcome to another episode of On the Couch with Henry Jennings. Today I Henry is talking to Dr Leslie Chong, CEO and MD of Imugene (IMU).

A very interesting look at an early stage biotech, where it is with trials and data, plus some words of advice on how to look at investing in biotechs in general. And a quick chat on Italian art to finish off. A great podcast and well worth a listen.
Leslie has 24 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.

Why not sign up for a free trial? Get access to expert insights and research and become a better investor.


Marcus Today Disclaimer

IMPORTANT
The content included on our website, podcasts and in our emails has been prepared to provide general information only and, as such, the specific needs, investment objectives or financial situation of any particular user accessing the Marcus Today website or associated emails have not been taken into consideration. Each individual user should obtain advice from their financial planner or advisor before acting on any information provided on the Marcus Today website or associated emails so that such individual users can obtain advice applicable to their personal circumstance from their own financial advisor. Please note that stocks can go down as well as up. Past results are not indicative of future performance and returns can be negative.

Disclaimer - Marcus holds POS shares.  Peter holds POS and PAN shares.

In the middle of a risk-off resources sell-down Marcus is on the Couch with Peter Harold, the CEO of Poseidon Nickel (POS).

Peter covers the nickel market, the resources sell-down, the state of play at POS and their forthcoming feasibility study.  He tops it off with three tips in the small cap resources space.

Enjoy!

Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

Marcus Today Disclaimer

IMPORTANT
The content included on our website, podcasts and in our emails has been prepared to provide general information only and, as such, the specific needs, investment objectives or financial situation of any particular user accessing the Marcus Today website or associated emails have not been taken into consideration. Each individual user should obtain advice from their financial planner or advisor before acting on any information provided on the Marcus Today website or associated emails so that such individual users can obtain advice applicable to their personal circumstance from their own financial advisor. Please note that stocks can go down as well as up. Past results are not indicative of future performance and returns can be negative.